Antibody Therapy Market Size, Share & Forecast
Report, 2026-2035

The Antibody Therapy Market was valued at USD 317.4 billion
in 2025 and is projected to reach USD 1.01 trillion by 2035, expanding at a
12.5% CAGR from 2026 to 2035. The market includes monoclonal antibodies,
antibody-drug conjugates, bispecific therapies, Fc-engineered therapies, and
other antibody-based formats. Growth is supported by continued adoption across
oncology, autoimmune and inflammatory disease, neurology, infectious disease,
and specialty-care settings.

Growing cancer and chronic-disease treatment demand is a
principal market driver. Antibody therapies are used across immune checkpoint
blockade, HER2 targeting, CD20 targeting, anti-angiogenesis therapy, and
antibody-delivered cytotoxic treatments. Cancer treatment frequently involves
repeated courses, combination regimens, and later-line options, supporting
sustained demand for specialty therapies. Autoimmune treatment also supports
recurring use because therapy can continue over extended periods and products
compete on selectivity, administration route, and disease control after
conventional treatment failure. Faster discovery and modality development are
broadening the industry pipeline through Fc engineering, site-specific
conjugation, optimized linkers, payload diversification, and multispecific
architectures.

Based on type, monoclonal antibodies are projected to reach
USD 936,101.6 million by 2035. The category maintains a broad installed base
across oncology, immunology, neurology, ophthalmology, and infectious disease.
Mature anti-TNF, anti-CD20, anti-HER2, and anti-VEGF therapies retain
substantial volume through biosimilar availability, while newer products
compete through target selectivity, administration convenience, dosing
frequency, and expanded indications. This combination allows monoclonal antibodies
to remain the foundational antibody format as higher-value ADCs and bispecific
therapies address more specialized treatment needs.

By application, oncology is projected to reach USD 516,947.9
million by 2035. The segment encompasses checkpoint inhibitors,
receptor-targeting monoclonal antibodies, anti-angiogenic therapies, ADCs, and
T-cell-engaging bispecifics. Its expansion reflects treatment movement into
earlier therapy lines, biomarker-directed approvals, combination regimens, and
tissue-agnostic development. ADCs and bispecifics can address antigen-defined
populations and patients whose disease does not respond adequately to standard
chemotherapy or single-agent immunotherapy. Their adoption depends on
diagnostic testing, safety monitoring, oncology-center capability, and
manufacturing capacity for complex linker-payload systems.

Browse complete table of content of this report @ https://www.gminsights.com/industry-analysis/antibody-therapy-market

North America Antibody Therapy Market is projected to reach
USD 419,451.5 million by 2035. The region benefits from early access to
innovative medicines, established specialty-care networks, biologics
reimbursement, and deep clinical-trial infrastructure. FDA expedited pathways
can support availability for serious diseases, while formulary controls,
utilization management, and biosimilar contracting influence treatment access.
Canada combines a smaller market base with growing biosimilar use and more structured
public reimbursement processes.

F. Hoffmann-La Roche, with over 11% market share in 2025,
holds a leading position in the Antibody Therapy Market. Roche maintains a
broad portfolio across oncology, hematology, ophthalmology, and neurology,
combining established antibody franchises with newer products such as Vabysmo,
Columvi, Polivy, and Ocrevus. Its continued R&D investment supports
portfolio renewal as mature products face biosimilar competition.

Roche maintains a broad portfolio spanning oncology,
hematology, ophthalmology, and neurology. Its position combines established
antibody franchises with Vabysmo, Columvi, Polivy, and Ocrevus. Continued
R&D investment supports portfolio renewal as mature products face
biosimilar competition.

Some of the major players in this market are AbbVie, Amgen,
AstraZeneca, Bristol Myers Squibb Company, Eli Lilly and Company,
GlaxoSmithKline, Johnson & Johnson, Merck & Co., Novartis, Pfizer,
Regeneron Pharmaceuticals, Sanofi, Seagen, and Takeda Pharmaceutical Company.

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware,
U.S., is a global market research and consulting service provider, offering
syndicated and custom research reports along with growth consulting services.
Our business intelligence and industry research reports offer clients with
penetrative insights and actionable market data specially designed and
presented to aid strategic decision making. These exhaustive reports are
designed via a proprietary research methodology and are available for key industries
such as chemicals, advanced materials, technology, renewable energy, and
biotechnology.

Contact Us

Aashit Tiwari

Corporate Sales, USA

Global Market Insights Inc.

Toll Free: +1-888-689-0688

USA: +1-302-846-7766

Europe: +44-742-759-8484

APAC: +65-3129-7718

Email: sales@gminsights.com